223 results on '"Andersson, B S"'
Search Results
2. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
3. Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy
4. Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors
5. Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients
6. Successful HLA haploidentical HSCT with post-transplant cyclophosphamide in Wiskott–Aldrich syndrome
7. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL
8. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR
9. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation
10. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial
11. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome
12. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts
13. Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect?
14. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response
15. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects
16. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma
17. From concept to standard of care using a nucleoside ana log-IV busulfan combination - now what?: 204
18. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs
19. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
20. The tissue localization ofm-amsa and its effect on thymidine incorporation in various tissuesin vivo
21. Romidepsin targets multiple survival signaling pathways in malignant T cells
22. Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines
23. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL
24. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR
25. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation
26. Regrowth of granulocyte-macrophage progenitor cells (GM-CFC) in suspension cultures of bone marrow depleted of GM-CFC with 4-hydroperoxycyclophosphamide (4-HC)*
27. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome
28. Treatment of patients (pts) with chronic myeloid leukemia (CML) and imatinib failure after developing BCR-ABL kinase mutations with allogeneic stem cell transplantation (ASCT)
29. Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic stem cell transplantation (ASCT) in patients (pts) with chronic myeloid leukemia (CML): No evidence for increased transplant-related toxicity
30. Influence of Allele Level HLA Typing on Unrelated Donor (UD) Transplantation for High Risk Myeloid Leukemias.
31. Progressive Disseminated Aspergillosis in a Bone Marrow Transplant Recipient: Response with a High-Dose Lipid Formulation of Amphotericin B
32. Symptomatic BKVirus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients
33. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
34. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.
35. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.
36. Effect of moderate ethanol intake on the heart: biochemical and morphological studies with isolated cardiomyocytes from rats fed a low-protein diet.
37. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.
38. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results.
39. Effectiveness of an Oral Triazole for Opportunistic Mold Infections in Patients with Cancer: Experience with SCH 39304
40. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia.
41. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.
42. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+cell dose, GVHD and disease response.
43. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity.
44. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.
45. High-dose neuroleptics for acute brain failure after intensive chemotherapy for acute leukemia.
46. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia.
47. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.
48. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study.
49. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect.
50. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin’s lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.